共 50 条
Consideration of stratification in confirmatory trials with time-to-event endpoint
被引:0
|作者:
Wang, Yizhuo
[1
]
Zhou, Xuan
[2
]
Guo, Zifang
[2
]
Fang, Xiao
[2
]
Liu, Fang
[2
]
Shen, Liji
[2
]
机构:
[1] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA
[2] Merck & Co Inc, Biostat & Res Decis Sci, North Wales, PA 19454 USA
关键词:
Stratification;
Stratified analysis;
Time-to-event;
PEMBROLIZUMAB PLUS CHEMOTHERAPY;
COLLAPSIBILITY;
MODEL;
D O I:
10.1016/j.cct.2024.107434
中图分类号:
R-3 [医学研究方法];
R3 [基础医学];
学科分类号:
1001 ;
摘要:
Stratification in randomization and analysis are widely employed to balance treatment groups in clinical trials. However, the potential power loss due to under-stratification or over-stratification has not been thoroughly evaluated in the typical setting of confirmatory clinical trials. In cases where there are too many strata and some have small sample sizes or a small number of events, it is common practice to combine these small strata during analysis. However, there is a lack of guidance on how those small strata should be combined. This paper presents extensive simulation studies to evaluate the impact of under-stratification or over-stratification on the power of survival analysis and the estimate of hazard ratio using stratified log-rank test and Cox PH model, respectively. The difference in power between stratified and unstratified log-rank tests is also investigated under different scenarios. Our results suggest that failing to consider prognostic stratification factors with strong effects, and/or accounting for non-prognostic factors such as noise and predictive factors, may reduce the power of the stratified log-rank test. Additionally, methods of combining small strata are explored and compared.
引用
收藏
页数:7
相关论文